Page last updated: 2024-10-31

mianserin and Hydrocephalus, Normal Pressure

mianserin has been researched along with Hydrocephalus, Normal Pressure in 1 studies

Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.

Hydrocephalus, Normal Pressure: A form of compensated hydrocephalus characterized clinically by a slowly progressive gait disorder (see GAIT DISORDERS, NEUROLOGIC), progressive intellectual decline, and URINARY INCONTINENCE. Spinal fluid pressure tends to be in the high normal range. This condition may result from processes which interfere with the absorption of CSF including SUBARACHNOID HEMORRHAGE, chronic MENINGITIS, and other conditions. (From Adams et al., Principles of Neurology, 6th ed, pp631-3)

Research Excerpts

ExcerptRelevanceReference
" Antidepressant and pravastatin were administered because of the patient's abulia and hypercholesterolemia, but neuroleptic malignant syndrome-like conditions developed."3.71[Unexpected drug-interaction]. ( Tajima, Y, 2002)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tajima, Y1

Other Studies

1 other study available for mianserin and Hydrocephalus, Normal Pressure

ArticleYear
[Unexpected drug-interaction].
    Rinsho byori. The Japanese journal of clinical pathology, 2002, Volume: 50, Issue:2

    Topics: Aged; Amoxapine; Anticholesteremic Agents; Antidepressive Agents, Second-Generation; Drug Interactio

2002